Journal article · 2025 · Open access

Alzheimer's disease drug development pipeline: 2025

Jeffrey L. Cummings, Yadi Zhou, Garam Lee, Kate Zhong, Jorge Ramón Fonseca Cacho, Amanda M. Leisgang Osse, Feixiong Cheng

Alzheimer s & Dementia Translational Research & Clinical Interventions, 11(2), e70098 · Published 1 April 2025 · DOI 10.1002/trc2.70098

Free PDFView at the publisherCite this paper

In brief

“Alzheimer's disease drug development pipeline: 2025” is a 2025 journal article by Jeffrey L. Cummings and 6 co-authors, published in Alzheimer s & Dementia Translational Research & Clinical Interventions. OpenAlex counts 262 citations as of 15 November 2026, which puts it in the top 1% of works published in 2025 by citations. It is open access under a CC BY-NC-ND licence: the full text is free to read at Alzheimer s & Dementia Translational Research & Clinical Interventions.

Citations
262
Most cited in
2026 (200)
Field-weighted impact
72.06
References
16
Authors
7

Abstract

Clinical trials for Alzheimer's disease (AD) must be registered on clinicaltrials.gov. The registry presents a variety of types of information related to the planned clinical trial. We assess clinicaltrials.gov to document and compare aspects of drug development across the AD pipeline. Currently, there are 138 drugs being assessed in 182 clinical trials in the AD pipeline. Biological disease-targeted therapies (DTTs) comprise 30% of the pipeline; small molecule DTTs account for 43% of the pipeline; drugs addressing cognitive enhancement account for 14% of the pipeline; and drugs aiming to ameliorate neuropsychiatric symptoms in participants with AD contribute 11% of the pipeline. Biomarkers are among the primary outcomes of 27% of active trials. Repurposed agents represent 33% of the pipeline agents. The pipeline has more trials and more drugs compared to the 2024 pipeline. Highlights: The 2025 Alzheimer's disease drug development pipeline hosts 182 trials and 138 novel drugs.The 2025 Alzheimer's disease drug development pipeline is diverse, with agents that address 15 basic disease processes.The 2025 Alzheimer's disease drug development pipeline has more trials and more drugs than the 2024 pipeline.Biomarkers play an important role in current trials to determine trial eligibility and as outcomes of trials.Repurposed agents comprise approximately one-third of the agents and trials in the 2025 Alzheimer's disease drug development pipeline.

Cite this paper

Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.

APA 7

Cummings, J. L., Zhou, Y., Lee, G., Zhong, K., Cacho, J. R. F., Osse, A. M. L., & Cheng, F. (2025). Alzheimer's disease drug development pipeline: 2025. Alzheimer s & Dementia Translational Research & Clinical Interventions, 11(2), e70098. https://doi.org/10.1002/trc2.70098

MLA 9

Cummings, Jeffrey L., et al. “Alzheimer's disease drug development pipeline: 2025.” Alzheimer s & Dementia Translational Research & Clinical Interventions, vol. 11, no. 2, 2025, p. e70098. https://doi.org/10.1002/trc2.70098.

Chicago

Cummings, Jeffrey L., Yadi Zhou, Garam Lee, Kate Zhong, Jorge Ramón Fonseca Cacho, Amanda M. Leisgang Osse, and Feixiong Cheng. 2025. “Alzheimer's disease drug development pipeline: 2025.” Alzheimer s & Dementia Translational Research & Clinical Interventions 11 (2): e70098. https://doi.org/10.1002/trc2.70098.

Harvard

Cummings, J. L. et al. (2025) ‘Alzheimer's disease drug development pipeline: 2025’, Alzheimer s & Dementia Translational Research & Clinical Interventions, 11(2), p. e70098. doi:10.1002/trc2.70098.

IEEE

J. L. Cummings et al., “Alzheimer's disease drug development pipeline: 2025,” Alzheimer s & Dementia Translational Research & Clinical Interventions, vol. 11, no. 2, p. e70098, 2025, doi: 10.1002/trc2.70098.

BibTeX

@article{cummings2025alzheimer,
  title     = {{Alzheimer's disease drug development pipeline: 2025}},
  author    = {Cummings, Jeffrey L. and Zhou, Yadi and Lee, Garam and Zhong, Kate and Cacho, Jorge Ramón Fonseca and Osse, Amanda M. Leisgang and Cheng, Feixiong},
  journal   = {Alzheimer s \& Dementia Translational Research \& Clinical Interventions},
  year      = {2025},
  volume    = {11},
  number    = {2},
  pages     = {e70098},
  doi       = {10.1002/trc2.70098},
  url       = {https://doi.org/10.1002/trc2.70098}
}

Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)

Topic and keywords

Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments

  • Alzheimer's disease
  • drug development pipeline
  • clinical trials
  • ClinicalTrials.gov
  • small molecule drugs
  • cognitive enhancement
  • neuropsychiatric symptoms
  • biomarkers

Work with this paper

Most-cited papers in Neuroscience

All highly cited Neuroscience papers

Questions about this paper

How do I cite this paper in APA style?

Cummings, J. L., Zhou, Y., Lee, G., Zhong, K., Cacho, J. R. F., Osse, A. M. L., & Cheng, F. (2025). Alzheimer's disease drug development pipeline: 2025. Alzheimer s & Dementia Translational Research & Clinical Interventions, 11(2), e70098. https://doi.org/10.1002/trc2.70098

How many times has this paper been cited?

262 times, according to OpenAlex on 15 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.

Is this paper free to read?

Yes. It is open access: read the free full text at Alzheimer s & Dementia Translational Research & Clinical Interventions.

Who wrote this paper?

Jeffrey L. Cummings, Yadi Zhou, Garam Lee, Kate Zhong, Jorge Ramón Fonseca Cacho, Amanda M. Leisgang Osse, Feixiong Cheng.

What is the DOI of this paper?

10.1002/trc2.70098. The permanent link is https://doi.org/10.1002/trc2.70098.

Bibliographic data from OpenAlex (CC0), last checked 15 November 2026. ResearchGuru does not host this paper; the links go to the publisher or the repository that does.